[2] Several of the initial partners and executives had previously been with the venture capital firm Morgan Holland.
[5][9] In 2013, Flagship helped fund the creation of Editas Medicine to use CRISPR gene editing for the development of pharmacological therapies, originally based on the genetic engineering protein Cas9.
Editas was founded by Feng Zhang, Jennifer Doudna, George Church, J. Keith Joung, and David R. Liu.
Doudna would later win the Nobel Prize in Chemistry in 2020 for her work on CRISPR, but quit Editas in 2014 over legal differences over intellectual property.
This article about a private equity or venture capital firm based in the United States is a stub.